Provided herein is a method for improving the health of an intestinal epithelial barrier using Aloe vera. The method may include administering Aloe vera extracts to intestinal epithelial cells. The decolorized aloe extract may be whole leaf extract, whole leaf dry extract, inner leaf dry extract, digested whole leaf extract, digested whole leaf dry extract, digested inner leaf dry extract, or a combination thereof.

High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas HPCs of NSAIA, for example, have demonstrated indications such as treating hair loss. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome.

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Compounds of the general formula

##STR00001##

are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

The present invention concerns the field of medications for the treatment of lesions and wounds of the skin and mucosa. The present invention relates to the use of a composition comprising a combination of a mucoadhesive component in the range from 0.05-20% by weight, an emollient component in the range from 0.02-20% by weight, hydrating and mucoprotective component i.e. hyaluronic acid in the range from 0.01-15% by weight and epithelizing component i.e. one or more amino acids in the range from 0.02-5% by weight in the treatment of epithelial lesions. The invention further comprises a composition comprising: carbomer (poly acrylic acid) in the range from 0.05% to 5%; sodium hyaluronate in the range from 0.01% to 15%; poloxamer (copolymers of ethylene oxide and propylene oxide) in the range from 0.1% to 15%; Oryza sativa extract in the range from 0.2% to 20%; and one or more amino acids in the range from 0.025% to 5%, wherein said percentages are by weight of the total weight of the product (w/w).

The present invention concerns the field of medications for the treatment of lesions and wounds of the skin and mucosa. The present invention relates to the use of a composition comprising a combination of a mucoadhesive component in the range from 0.05-20% by weight, an emollient component in the range from 0.02-20% by weight, hydrating and mucoprotective component i.e. hyaluronic acid in the range from 0.01-15% by weight and epithelizing component i.e. one or more amino acids in the range from 0.02-5% by weight in the treatment of epithelial lesions. The invention further comprises a composition comprising: carbomer (poly acrylic acid) in the range from 0.05% to 5%; sodium hyaluronate in the range from 0.01% to 15%; poloxamer (copolymers of ethylene oxide and propylene oxide) in the range from 0.1% to 15%; Oryza sativa extract in the range from 0.2% to 20%; and one or more amino acids in the range from 0.025% to 5%, wherein said percentages are by weight of the total weight of the product (w/w).

Compositions and methods are provided for reducing fibrosis in a mammal by administering a therapeutic dose of a combination of agents to block interleukin-6 (IL-6), and an immune checkpoint inhibitor; wherein the checkpoint inhibitor comprising an agent that blocks programmed cell death protein 1 (PD1), blocks PD1 ligand 1 (PDL1), or blocks CD47/SIRPa pathway.

Compositions and methods are provided for reducing fibrosis in a mammal by administering a therapeutic dose of a combination of agents to block interleukin-6 (IL-6), and an immune checkpoint inhibitor; wherein the checkpoint inhibitor comprising an agent that blocks programmed cell death protein 1 (PD1), blocks PD1 ligand 1 (PDL1), or blocks CD47/SIRPa pathway.